Lupin Obtains the US FDA Approval for Loteprednol Etabonate Ophthalmic Suspension
Shots:
- Lupin has obtained the US FDA approval for the ANDA of Loteprednol Etabonate Ophthalmic Suspension, 0.2%
- The company’s approved generic is equivalent to the reference listed drug (RLD) of Bausch & Lomb’s Alrex Ophthalmic Suspension, 0.2% and will be manufactured at Pithampur (India)
- The generic, Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is approved for the providing temporary relief to the patients having symptoms of seasonal allergic conjunctivitis
Ref: Lupin | Image: Lupin
Related News:- Kala Pharmaceuticals' Eysuvis (loteprednol etabonate ophthalmic suspension) Receives US FDA's Approval for Dry Eye Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
